ImmusanT Gets $40M From Arch, Vatera to Continue Celiac Vaccine Quest

08:55 EST 14 Nov 2017 | Xconomy

ImmusanT has spent years developing an immunotherapy meant to help people with celiac disease tolerate gluten. Today, on the verge of its most substantial clinical test to date, the company has also come up with its biggest round of funding from some well-known backers. Arch Venture Partners has joined previous ImmusanT backer Vatera Healthcare Partners […]

Original Article: ImmusanT Gets $40M From Arch, Vatera to Continue Celiac Vaccine Quest


More From BioPortfolio on "ImmusanT Gets $40M From Arch, Vatera to Continue Celiac Vaccine Quest"

Quick Search


Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...